Chemistry Reference
In-Depth Information
P
= 0.03
140
100
75 min
60
45 min
20
0
Before
After
Figure 9.7
increase of the mean time of first rise of hydrogen in breath by intake of
L. casei
shirota. Patients with irritable bowel syndrome were administered a fermented
milk drink for 6 weeks. before and after ingestion of a fermented beverage, a
lactulose breath test was undergone. the median time of first rise in breath hydro-
gen before and after intake of probiotic drink was 45 and 75 min, respectively.
(from barrett, J.s. et al.,
World J. Gastroenterol.,
14, 5020-5024, 2008. With
permission.
18
)
Candy et al.
20
reported a case study that
L. casei
Shirota is effective for the
patient with short bowel at 12 months of age. Short bowel syndrome is characterized
by impaired digestion and absorption mainly due to extensive bowel resection. The
subject ingested 15 mL of a fermented milk beverage containing more than 1.5 × 10
9
cells of
L. casei
Shirota three times a day. As a result, abundant
L. casei
Shirota was
detected from patient's stool after 3 days, stool frequency decreased from 12 to 4 per
day, and the concentration of sodium in the urine increased. After 2 years of taking
L. casei
Shirota, the patient's development became normal.
Matsuzaki et al.
21
conducted a study to determine whether or not consump-
tion of fermented milk containing
L. casei
Shirota is effective for patients
with human T-cell lymphotropic virus type-1-associated myelopathy (HAM)
or tropical spastic paraparesis (TSP). It has been reported that HAM/TSP is
a chronic progressive myelopathy.
22
The precise mechanism that causes HAM/
TSP is not clear, but it is thought that virus-host immunological interactions are
most important in causing this disease. In the study, 10 patients with HAM/TSP
were administered 4.0 × 10
10
cells of
L. casei
Shirota twice a day for 4 weeks.
Significant improvement of urinary symptoms and spasticity were seen after
L.
casei
Shirota administration.
Naito et al.
23
evaluated whether or not
L . casei
Shirota could enhance the effect of
epirubicin (an anticancer drug). After transurethral resection for superficial bladder
cancer, patients were randomly administered either epirubicin intravesically or epiru-
bicin intravesically plus oral administration of
L. casei
Shirota preparation (3 g/day)
for 1 year. As a result, there were no serious adverse drug reactions in either group,
and the 3-year recurrence-free rates in the epirubicin plus
L. casei
Shirota group were
significantly higher than that of the epirubicin group (74.6 percent vs. 59.9 percent).
